Shots:

• The approval follows the trials which involves assessing of HLX13 vs originator ipilimumab to evaluate its pharmacology- pharmacokinetics and toxicokinetics profiles- immunogenicity- and toxicity
• The study resulted in biosimilarity data in terms of in vivo and in vitro pharmacology- PK- toxicokinetics- immunogenicity and toxicity characteristics
• HLX13 is a recombinant anti-CTLA-4 fully human mAb injection resulting in  T cell activation in anti-tumour immune response and is developed under Chinese Biosimilar Guidelines approved for unresectable or metastatic melanoma- advanced RCC- MSI-H or dMMR Mcc and adjuvant treatment of melanoma

Click here to read full press release/ article | Ref: Henlius | Image: Twitter